[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625705":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":25,"collaborators":29,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":10},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Revascularization Group",null,"Coronary artery bypass grafting (CABG) or Percutaneous coronary intervention (PCI) according to standard of care.",{"label":13,"type":10,"description":14,"interventionNames":10},"Medical Therapy Group","Guideline-directed medical therapy without revascularization",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Jin Wu","CONTACT","010-17888838056","wujin1996@126.com",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Ye-Jun Wu","010-18800181620","wyejun1999@163.com",{"type":26,"investigatorFullName":27,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Xiao Hui Zhang","Professor",[30,32,34,36,38],{"name":31,"class":6},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"name":33,"class":6},"Beijing Anzhen Hospital",{"name":35,"class":6},"Peking University Third Hospital",{"name":37,"class":6},"Chinese PLA General Hospital",{"name":39,"class":6},"Peking Union Medical College","100625705","development-and-prospective-validation-of-an-ai-model-for-prognosis-in-itp-patients-undergoing-coronary-revascularization-100625705",false,"NCT07426107","Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization","An Artificial Intelligence-Enhanced Longitudinal Cohort Study to Optimize Revascularization Decisions in Patients With Coronary Artery Disease and Immune Thrombocytopenia (The ITP-CAD AI-REVASC Study)","ITP with CAD","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosis of primary Immune Thrombocytopenia (ITP) according to international working group criteria.\n3. Diagnosis of Coronary Artery Disease (stable angina or Acute Coronary Syndrome) confirmed by coronary angiography.\n4. The diagnosis of ITP must be established and documented prior to the diagnosis of CAD.\n5. Capable of providing informed consent (for prospective enrollment and data collection).\n\nExclusion Criteria:\n\n1. Secondary causes of thrombocytopenia (e.g., drug-induced, hematologic malignancy, hypersplenism, liver disease).\n2. Conditions requiring long-term therapeutic anticoagulation (e.g., atrial fibrillation, mechanical heart valve).\n3. Life expectancy less than 1 year due to non-cardiovascular disease.\n4. Inability to comply with follow-up.\n5. Inability to give informed consent.\n6. Pregnancy or breastfeeding.\n7. A history of Type 2 Myocardial Infarction prior to the index treatment decision.","ALL","18 Years","90 Years",{"count":52,"type":53},600,"ESTIMATED","OBSERVATIONAL","This study employs a dual-cohort design to develop and validate a prognostic model for Major Adverse Cardiovascular Events (MACE) following revascularization in immune thrombocytopenia (ITP) patients with Coronary Artery Disease (CAD). The model will be developed and trained using a retrospective multi-center cohort (development\u002Ftraining cohort). Its performance will then be prospectively validated in a separate, consecutively enrolled prospective cohort (validation cohort). The goal is to create an AI-based tool to assist in personalized risk assessment and decision-making for this high-risk population.",[57,58],"Immune Thrombocytopenic Purpura","Coronary Artery Disease",[60,61,62,63,64],"immune thrombocytopenia","coronary artery disease","coronary revascularization","prognostic model","MACE","NOT_YET_RECRUITING","2026-02-15",{"date":68,"type":69},"2026-02-23","ACTUAL",{"date":71,"type":53},"2026-02-25",{"date":73,"type":53},"2029-02-25",{"name":27,"class":6}]